Episode Details

AbbVie just spent $11 billion to bolster its immunology arsenal, betting big on zumilokibart—a potential eczema game-changer that could outperform current treatments with fewer injections. With Skyrizi and Rinvoq still raking in $31 billion annually before patent cliffs hit in the next decade, the move makes strategic sense. Leveraging their proven immunology playbook—think Humira’s $21 billion peak—they’re positioning for the future, even as they diversify into anti-obesity and migraine therapies like Qulipta. Plus, with 50+ years of dividend growth, AbbVie remains a reliable income play—even if zumilokibart doesn’t deliver, their pipeline and financial health keep them in the driver’s seat.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/4eedf3fa582f9df7